Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reviews

Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation

Jongwook Oh, Jong Man Kim

Clin Mol Hepatol. 2020;26(1):1-6. Published online March 26, 2019

Web of Science 26 Crossref 26

DOI: https://doi.org/10.3350/cmh.2019.0023

The fibrogenic process and the unleashing of acute-on-chronic liver failure

Guillermo Nahúm López-Sánchez, Mayra Dóminguez-Pérez, Misael Uribe, Natalia Nuño-Lámbarri

Clin Mol Hepatol. 2020;26(1):7-15. Published online June 14, 2019

Web of Science 10 Crossref 11

DOI: https://doi.org/10.3350/cmh.2019.0011

Extrahepatic manifestations of hepatitis E virus: An overview

Fotios S. Fousekis, Ioannis V. Mitselos, Dimitrios K. Christodoulou

Clin Mol Hepatol. 2020;26(1):16-23. Published online October 11, 2019

Web of Science 41 Crossref 40

DOI: https://doi.org/10.3350/cmh.2019.0082

Original Articles

A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea

Jae Seung Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jin Sil Seong, Kwang-Hyub Han, Do Young Kim

Clin Mol Hepatol. 2020;26(1):24-32. Published online May 20, 2019

Web of Science 30 Crossref 30

DOI: https://doi.org/10.3350/cmh.2018.0065

Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection

Hye Soo Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Young Nyun Park, Dai Hoon Han, Kyung Sik Kim, Jin Sub Choi, Gi Hong Choi, Hyon-Suk Kim

Clin Mol Hepatol. 2020;26(1):33-44. Published online June 27, 2019

Web of Science 18 Crossref 15

DOI: https://doi.org/10.3350/cmh.2018.0073

Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line

Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti

Clin Mol Hepatol. 2020;26(1):45-53. Published online September 30, 2019

Web of Science 21 Crossref 17

DOI: https://doi.org/10.3350/cmh.2019.0031

Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard

Jamak Modaresi Esfeh, Kaveh Hajifathalian, Kianoush Ansari-Gilani

Clin Mol Hepatol. 2020;26(1):54-59. Published online November 15, 2019

Web of Science 48 Crossref 50

DOI: https://doi.org/10.3350/cmh.2019.0039

Influence of some methylated hepatocarcinogenesis-related genes on the response to antiviral therapy and development of fibrosis in chronic hepatitis C patients

Waleed Seif Eldin Mohamed Mostafa, Mohammed Hassan Saiem Al-Dahr, Dalia Abdel Hamid Omran, Zeinab Fathy Abdullah, Suzan Hamdy Elmasry, Mohamed Nabil Ibrahim

Clin Mol Hepatol. 2020;26(1):60-69. Published online October 22, 2019

Web of Science 4 Crossref 4

DOI: https://doi.org/10.3350/cmh.2019.0051

Letters to the Editor

The management of polycystic liver disease by tolvaptan

Tsuneo Takenaka, Soichiro Miura, Masaki Kitajima

Clin Mol Hepatol. 2020;26(1):70-73. Published online June 13, 2019

Web of Science 8 Crossref 8

DOI: https://doi.org/10.3350/cmh.2019.0026

Hyperammonemic encephalopathy: An unusual presentation of fibrolamellar hepatocellular carcinoma

Nimish Thakral, Douglas A. Simonetto

Clin Mol Hepatol. 2020;26(1):74-77. Published online August 16, 2019

Web of Science 7 Crossref 10

DOI: https://doi.org/10.3350/cmh.2018.0042

Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with myeloproliferative neoplasms

Jaejun Lee, Pil Soo Sung, Ki-Seong Eom, Hyun Yang, Soon Kyu Lee, Aung Hlaing Bwa, Angelo Lozada, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon

Clin Mol Hepatol. 2020;26(1):78-82. Published online November 26, 2019

Web of Science 5 Crossref 4

DOI: https://doi.org/10.3350/cmh.2019.0078

Viewed By 5015	MAFLD: How is it different from NAFLD?
Viewed By 4843	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4792	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4496	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4466	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Previous issues